DBVT News
Archived Headlines
- Ritter Pharmaceuticals prices IPO at downwardly revised price of $5; now has $39 million market cap 06/24/15
- Ritter Pharmaceuticals drops proposed IPO price; market cap down 45% to $39 million 06/19/15
- US IPO Weekly Recap: With just 3 IPOs, more companies postpone than go public 10/24/14
- DBV Technologies prices US IPO at $21.64, below expectations 10/22/14
- Peanut allergy biotech DBV Technologies sets terms for $98 million US IPO 10/15/14
See more
US IPO Weekly Recap: A bad week besides biotech
Biotech companies lead a weak week in IPOs. So far this year, 127 companies have come public, and the average first-day pop has been about 16%. In the past two weeks, 8 of...read more
Go nuts!: Aimmune Therapeutics prices upsized IPO at $16, the high end of the range
Aimmune Therapeutics, which is developing an oral immunotherapy to desensitize peanut allergies, raised $160 million by offering 10 million shares at $16.00, the high end of the range of $14 to $16. Aimmune Therapeutics plans to list on the Nasdaq under the...read more
Peanut allergy biotech Aimmune Therapeutics sets terms for $125 million IPO
Aimmune Therapeutics, which is developing an oral immunotherapy designed to lessen the effects of peanut allergies, announced terms for its IPO on Monday. The Brisbane, CA-based company plans to raise $125 million by offering 8.3 million shares at a price...read more
Peanut allergy biotech Aimmune Therapeutics files for a $115 million IPO
Aimmune Therapeutics, which is developing an oral immunotherapy designed to lessen the effects of peanut allergies, filed on Monday with the SEC to raise up to $115 million in an initial public offering. The company notes that it may face competition DBV...read more